Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:IZTC NASDAQ:TROV NASDAQ:ZIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.40-6.8%$5.16$7.96▼$24.15$22.19M0.6315,685 shs66,297 shsIZTCInvizyne Technologies$8.18+4.5%$9.55$8.50▼$23.00$51.14MN/A37,647 shs8,061 shsTROVCardiff Oncology$1.56$16.75$0.70▼$3.46$17.18M1.04648,892 shs885,068 shsZIVOZIVO Bioscience$4.30+16.5%$3.30$1.11▼$19.65$17.85M0.073,546 shs5,142 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-6.78%+3.04%-10.57%-29.03%+83.33%IZTCInvizyne Technologies+4.47%+11.29%-17.54%+12.83%-10.60%TROVCardiff Oncology0.00%0.00%0.00%-9.83%-49.68%ZIVOZIVO Bioscience+16.53%+16.53%+4.76%-47.88%-69.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.40-6.8%$5.16$7.96▼$24.15$22.19M0.6315,685 shs66,297 shsIZTCInvizyne Technologies$8.18+4.5%$9.55$8.50▼$23.00$51.14MN/A37,647 shs8,061 shsTROVCardiff Oncology$1.56$16.75$0.70▼$3.46$17.18M1.04648,892 shs885,068 shsZIVOZIVO Bioscience$4.30+16.5%$3.30$1.11▼$19.65$17.85M0.073,546 shs5,142 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-6.78%+3.04%-10.57%-29.03%+83.33%IZTCInvizyne Technologies+4.47%+11.29%-17.54%+12.83%-10.60%TROVCardiff Oncology0.00%0.00%0.00%-9.83%-49.68%ZIVOZIVO Bioscience+16.53%+16.53%+4.76%-47.88%-69.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AIZTCInvizyne Technologies 0.00N/AN/AN/ATROVCardiff Oncology 0.00N/AN/AN/AZIVOZIVO Bioscience 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ATROVCardiff Oncology$250K68.71N/AN/A$0.94 per share1.66ZIVOZIVO Bioscience$15.85K1,126.41N/AN/A($0.81) per share-5.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/ATROVCardiff Oncology-$16.41M-$2.80N/AN/AN/A-3,688.31%-202.00%-122.92%N/AZIVOZIVO Bioscience-$7.78M-$1.71N/AN/AN/AN/AN/A-2,240.92%9/2/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/AZIVOZIVO BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78IZTCInvizyne TechnologiesN/AN/AN/ATROVCardiff Oncology0.122.372.37ZIVOZIVO BioscienceN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%IZTCInvizyne TechnologiesN/ATROVCardiff Oncology9.99%ZIVOZIVO Bioscience12.83%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%IZTCInvizyne TechnologiesN/ATROVCardiff Oncology0.60%ZIVOZIVO Bioscience48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionNo DataIZTCInvizyne Technologies296.25 millionN/AN/ATROVCardiff OncologyN/A11.01 millionN/ANot OptionableZIVOZIVO Bioscience104.15 million2.91 millionNot OptionableTROV, IZTC, ALVR, and ZIVO HeadlinesRecent News About These CompaniesZivo Bioscience, Inc. Announces Transition to OTCID MarketplaceMay 12, 2026 | businesswire.comZivo Bioscience Inc. WtApril 11, 2026 | barrons.comZIVO Bioscience Provides Special Letter to ShareholdersMarch 27, 2026 | businesswire.comMaxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)December 15, 2025 | theglobeandmail.comZIVO Bioscience releases letter to shareholdersSeptember 14, 2025 | wattagnet.comWZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10, 2025 | businesswire.comZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 6, 2025 | businesswire.comZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comTuesday's Insider Activity: Top Buys and Sells in US Stocks RevealedJanuary 1, 2025 | investing.comZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaDecember 20, 2024 | businesswire.comZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023March 18, 2024 | investorplace.comHarmony Biosciences HoldingsMarch 4, 2024 | forbes.comRegencell Bioscience Holdings Ltd RGCFebruary 1, 2024 | morningstar.comMZIVO Bioscience Announces Uplisting to OTCQB MarketJanuary 29, 2024 | finance.yahoo.comIdeaya BiosciencesJanuary 18, 2024 | forbes.comDare Bioscience Inc DAREJanuary 14, 2024 | morningstar.comMZivo Bioscience Inc (ZIVO) USD0.001November 11, 2023 | hl.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026What's Behind the Social Media Controversy Surrounding IonQ?By Nathan Reiff | June 15, 2026Lululemon’s China Backlash May Be Hiding a Bigger Valuation StoryBy Sam Quirke | June 22, 2026TROV, IZTC, ALVR, and ZIVO Company DescriptionsAlloVir NASDAQ:ALVR$4.40 -0.32 (-6.78%) As of 06/22/2026AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Invizyne Technologies NASDAQ:IZTC$8.18 +0.35 (+4.47%) As of 06/22/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Cardiff Oncology NASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.ZIVO Bioscience NASDAQ:ZIVO$4.30 +0.61 (+16.53%) As of 06/23/2026 03:50 PM EasternZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
